Business Standard

Indian pharma has bounced back from lockdown lows. What led to turnaround?

From the lows of the lockdown, the industry has seen a robust bounceback

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Premium

In October, the Indian pharma market (IPM) clocked a strong 9.6 per cent growth after growing 4.5 per cent in September and 2.2 per cent in August

Sohini Das Mumbai
The domestic pharma market has not only recovered from the lows of the lockdown-hit months of April-June, but is likely to do better in the second half of the fiscal.

Pandemic blues seem to be a thing of the past as the domestic drug market showed resilience in the last three months, maintaining a growth momentum. In October, the Indian pharma market (IPM) clocked a strong 9.6 per cent growth after growing 4.5 per cent in September and 2.2 per cent in August.

Compare this with the lockdown-hit months when the IPM volume growth was down 17 per cent in April and

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 27 2020 | 6:10 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com